Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Supply, Demand and Key Producers, 2023-2029

Page: 108

Published Date: 23 Jan 2023

Category: Pharma & Healthcare

PDF Download

Get FREE Sample

Customize Request

Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags

Description

The global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

AAV is transformed from a naturally occurring virus into a delivery mechanism for gene therapy. The viral DNA is replaced with new DNA, and it becomes a precisely coded vector and is no longer considered a virus, as most of the viral components have been replaced. The AAV Vector-Based Gene Therapy market size is anticipated to shoot up exponentially attributing to an increase in the approval of a growing number of gene therapies and readily adoption on approval, ability to treat a broad array of conditions, increasing prevalence of diseases, convenient one-time dosing approach and curative treatment options.

This report studies the global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Adeno-Associated Virus (AAV) Vector-Based Gene Therapy, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy that contribute to its increasing demand across many markets.

Highlights and key features of the study
Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy total market, 2018-2029, (USD Million)
Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy total market by region & country, CAGR, 2018-2029, (USD Million)
U.S. VS China: Adeno-Associated Virus (AAV) Vector-Based Gene Therapy total market, key domestic companies and share, (USD Million)
Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy revenue by player and market share 2018-2023, (USD Million)
Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy total market by Type, CAGR, 2018-2029, (USD Million)
Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy total market by Application, CAGR, 2018-2029, (USD Million)
This reports profiles major players in the global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include BioMarin Pharmaceutical, Sangamo Therapeutics, Amicus Therapeutics, Roche, Pfizer, NightstaRx, MeiraGTx, Sarepta Therapeutics and Neurocrine Biosciences, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market, By Region:
    United States
    China
    Europe
    Japan
    South Korea
    ASEAN
    India
    Rest of World

Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market, Segmentation by Type
    Single-stranded AAV (ssAAV)
    Self-complementary AAV (scAAV)

Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market, Segmentation by Application
    Hemophilia
    Ophthalmology
    Lysosomal Storage Disorders
    Neurological Disorders
    Others

Companies Profiled:
    BioMarin Pharmaceutical
    Sangamo Therapeutics
    Amicus Therapeutics
    Roche
    Pfizer
    NightstaRx
    MeiraGTx
    Sarepta Therapeutics
    Neurocrine Biosciences
    Voyager Therapeutics
    Asklepios Biopharmaceutical

Key Questions Answered
1. How big is the global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market?
2. What is the demand of the global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market?
3. What is the year over year growth of the global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market?
4. What is the total value of the global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market?
5. Who are the major players in the global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market?
6. What are the growth factors driving the market demand?

Table of Contents

1 Supply Summary
    1.1 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Introduction
    1.2 World Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size & Forecast (2018 & 2022 & 2029)
    1.3 World Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Total Market by Region (by Headquarter Location)
        1.3.1 World Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region (2018-2029), (by Headquarter Location)
        1.3.2 United States Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (2018-2029)
        1.3.3 China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (2018-2029)
        1.3.4 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (2018-2029)
        1.3.5 Japan Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (2018-2029)
        1.3.6 South Korea Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (2018-2029)
        1.3.7 ASEAN Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (2018-2029)
        1.3.8 India Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (2018-2029)
    1.4 Market Drivers, Restraints and Trends
        1.4.1 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Drivers
        1.4.2 Factors Affecting Demand
        1.4.3 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Major Market Trends
    1.5 Influence of COVID-19 and Russia-Ukraine War
        1.5.1 Influence of COVID-19
        1.5.2 Influence of Russia-Ukraine War

2 Demand Summary
    2.1 World Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value (2018-2029)
    2.2 World Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value by Region
        2.2.1 World Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value by Region (2018-2023)
        2.2.2 World Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value Forecast by Region (2024-2029)
    2.3 United States Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value (2018-2029)
    2.4 China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value (2018-2029)
    2.5 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value (2018-2029)
    2.6 Japan Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value (2018-2029)
    2.7 South Korea Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value (2018-2029)
    2.8 ASEAN Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value (2018-2029)
    2.9 India Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value (2018-2029)

3 World Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Companies Competitive Analysis
    3.1 World Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Player (2018-2023)
    3.2 Industry Rank and Concentration Rate (CR)
        3.2.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Industry Rank of Major Players
        3.2.2 Global Concentration Ratios (CR4) for Adeno-Associated Virus (AAV) Vector-Based Gene Therapy in 2022
        3.2.3 Global Concentration Ratios (CR8) for Adeno-Associated Virus (AAV) Vector-Based Gene Therapy in 2022
    3.3 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Company Evaluation Quadrant
    3.4 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market: Overall Company Footprint Analysis
        3.4.1 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market: Region Footprint
        3.4.2 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market: Company Product Type Footprint
        3.4.3 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market: Company Product Application Footprint
    3.5 Competitive Environment
        3.5.1 Historical Structure of the Industry
        3.5.2 Barriers of Market Entry
        3.5.3 Factors of Competition
    3.6 Mergers, Acquisitions Activity

4 United States VS China VS Rest of the World (by Headquarter Location)
    4.1 United States VS China: Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Comparison (by Headquarter Location)
        4.1.1 United States VS China: Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
        4.1.2 United States VS China: Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share Comparison (2018 & 2022 & 2029)
    4.2 United States Based Companies VS China Based Companies: Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value Comparison
        4.2.1 United States VS China: Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value Comparison (2018 & 2022 & 2029)
        4.2.2 United States VS China: Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value Market Share Comparison (2018 & 2022 & 2029)
    4.3 United States Based Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Companies and Market Share, 2018-2023
        4.3.1 United States Based Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Companies, Headquarters (States, Country)
        4.3.2 United States Based Companies Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, (2018-2023)
    4.4 China Based Companies Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue and Market Share, 2018-2023
        4.4.1 China Based Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Companies, Company Headquarters (Province, Country)
        4.4.2 China Based Companies Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, (2018-2023)
    4.5 Rest of World Based Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Companies and Market Share, 2018-2023
        4.5.1 Rest of World Based Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Companies, Headquarters (States, Country)
        4.5.2 Rest of World Based Companies Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, (2018-2023)

5 Market Analysis by Type
    5.1 World Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Overview by Type: 2018 VS 2022 VS 2029
    5.2 Segment Introduction by Type
        5.2.1 Single-stranded AAV (ssAAV)
        5.2.2 Self-complementary AAV (scAAV)
    5.3 Market Segment by Type
        5.3.1 World Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2018-2023)
        5.3.2 World Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2024-2029)
        5.3.3 World Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Type (2018-2029)

6 Market Analysis by Application
    6.1 World Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Overview by Application: 2018 VS 2022 VS 2029
    6.2 Segment Introduction by Application
        6.2.1 Hemophilia
        6.2.2 Ophthalmology
        6.2.3 Lysosomal Storage Disorders
        6.2.4 Neurological Disorders
        6.2.5 Neurological Disorders
    6.3 Market Segment by Application
        6.3.1 World Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2018-2023)
        6.3.2 World Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2024-2029)
        6.3.3 World Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2018-2029)

7 Company Profiles
    7.1 BioMarin Pharmaceutical
        7.1.1 BioMarin Pharmaceutical Details
        7.1.2 BioMarin Pharmaceutical Major Business
        7.1.3 BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product and Services
        7.1.4 BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2018-2023)
        7.1.5 BioMarin Pharmaceutical Recent Developments/Updates
        7.1.6 BioMarin Pharmaceutical Competitive Strengths & Weaknesses
    7.2 Sangamo Therapeutics
        7.2.1 Sangamo Therapeutics Details
        7.2.2 Sangamo Therapeutics Major Business
        7.2.3 Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product and Services
        7.2.4 Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2018-2023)
        7.2.5 Sangamo Therapeutics Recent Developments/Updates
        7.2.6 Sangamo Therapeutics Competitive Strengths & Weaknesses
    7.3 Amicus Therapeutics
        7.3.1 Amicus Therapeutics Details
        7.3.2 Amicus Therapeutics Major Business
        7.3.3 Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product and Services
        7.3.4 Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2018-2023)
        7.3.5 Amicus Therapeutics Recent Developments/Updates
        7.3.6 Amicus Therapeutics Competitive Strengths & Weaknesses
    7.4 Roche
        7.4.1 Roche Details
        7.4.2 Roche Major Business
        7.4.3 Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product and Services
        7.4.4 Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2018-2023)
        7.4.5 Roche Recent Developments/Updates
        7.4.6 Roche Competitive Strengths & Weaknesses
    7.5 Pfizer
        7.5.1 Pfizer Details
        7.5.2 Pfizer Major Business
        7.5.3 Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product and Services
        7.5.4 Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2018-2023)
        7.5.5 Pfizer Recent Developments/Updates
        7.5.6 Pfizer Competitive Strengths & Weaknesses
    7.6 NightstaRx
        7.6.1 NightstaRx Details
        7.6.2 NightstaRx Major Business
        7.6.3 NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product and Services
        7.6.4 NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2018-2023)
        7.6.5 NightstaRx Recent Developments/Updates
        7.6.6 NightstaRx Competitive Strengths & Weaknesses
    7.7 MeiraGTx
        7.7.1 MeiraGTx Details
        7.7.2 MeiraGTx Major Business
        7.7.3 MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product and Services
        7.7.4 MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2018-2023)
        7.7.5 MeiraGTx Recent Developments/Updates
        7.7.6 MeiraGTx Competitive Strengths & Weaknesses
    7.8 Sarepta Therapeutics
        7.8.1 Sarepta Therapeutics Details
        7.8.2 Sarepta Therapeutics Major Business
        7.8.3 Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product and Services
        7.8.4 Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2018-2023)
        7.8.5 Sarepta Therapeutics Recent Developments/Updates
        7.8.6 Sarepta Therapeutics Competitive Strengths & Weaknesses
    7.9 Neurocrine Biosciences
        7.9.1 Neurocrine Biosciences Details
        7.9.2 Neurocrine Biosciences Major Business
        7.9.3 Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product and Services
        7.9.4 Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2018-2023)
        7.9.5 Neurocrine Biosciences Recent Developments/Updates
        7.9.6 Neurocrine Biosciences Competitive Strengths & Weaknesses
    7.10 Voyager Therapeutics
        7.10.1 Voyager Therapeutics Details
        7.10.2 Voyager Therapeutics Major Business
        7.10.3 Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product and Services
        7.10.4 Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2018-2023)
        7.10.5 Voyager Therapeutics Recent Developments/Updates
        7.10.6 Voyager Therapeutics Competitive Strengths & Weaknesses
    7.11 Asklepios Biopharmaceutical
        7.11.1 Asklepios Biopharmaceutical Details
        7.11.2 Asklepios Biopharmaceutical Major Business
        7.11.3 Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product and Services
        7.11.4 Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2018-2023)
        7.11.5 Asklepios Biopharmaceutical Recent Developments/Updates
        7.11.6 Asklepios Biopharmaceutical Competitive Strengths & Weaknesses

8 Industry Chain Analysis
    8.1 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Industry Chain
    8.2 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Upstream Analysis
    8.3 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Midstream Analysis
    8.4 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Downstream Analysis

9 Research Findings and Conclusion

10 Appendix
    10.1 Methodology
    10.2 Research Process and Data Source
    10.3 Disclaimer

Table of Figures

List of Tables
    Table 1. World Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)
    Table 2. World Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)
    Table 3. World Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)
    Table 4. World Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share by Region (2018-2023), (by Headquarter Location)
    Table 5. World Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share by Region (2024-2029), (by Headquarter Location)
    Table 6. Major Market Trends
    Table 7. World Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)
    Table 8. World Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value by Region (2018-2023) & (USD Million)
    Table 9. World Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value Forecast by Region (2024-2029) & (USD Million)
    Table 10. World Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue by Player (2018-2023) & (USD Million)
    Table 11. Revenue Market Share of Key Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Players in 2022
    Table 12. World Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Industry Rank of Major Player, Based on Revenue in 2022
    Table 13. Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Company Evaluation Quadrant
    Table 14. Head Office of Key Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Player
    Table 15. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market: Company Product Type Footprint
    Table 16. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market: Company Product Application Footprint
    Table 17. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Mergers & Acquisitions Activity
    Table 18. United States VS China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)
    Table 19. United States VS China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)
    Table 20. United States Based Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Companies, Headquarters (States, Country)
    Table 21. United States Based Companies Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, (2018-2023) & (USD Million)
    Table 22. United States Based Companies Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share (2018-2023)
    Table 23. China Based Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Companies, Headquarters (Province, Country)
    Table 24. China Based Companies Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, (2018-2023) & (USD Million)
    Table 25. China Based Companies Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share (2018-2023)
    Table 26. Rest of World Based Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Companies, Headquarters (States, Country)
    Table 27. Rest of World Based Companies Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, (2018-2023) & (USD Million)
    Table 28. Rest of World Based Companies Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share (2018-2023)
    Table 29. World Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type, (USD Million), 2018 & 2022 & 2029
    Table 30. World Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2018-2023) & (USD Million)
    Table 31. World Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type (2024-2029) & (USD Million)
    Table 32. World Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application, (USD Million), 2018 & 2022 & 2029
    Table 33. World Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2018-2023) & (USD Million)
    Table 34. World Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application (2024-2029) & (USD Million)
    Table 35. BioMarin Pharmaceutical Basic Information, Area Served and Competitors
    Table 36. BioMarin Pharmaceutical Major Business
    Table 37. BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product and Services
    Table 38. BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 39. BioMarin Pharmaceutical Recent Developments/Updates
    Table 40. BioMarin Pharmaceutical Competitive Strengths & Weaknesses
    Table 41. Sangamo Therapeutics Basic Information, Area Served and Competitors
    Table 42. Sangamo Therapeutics Major Business
    Table 43. Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product and Services
    Table 44. Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 45. Sangamo Therapeutics Recent Developments/Updates
    Table 46. Sangamo Therapeutics Competitive Strengths & Weaknesses
    Table 47. Amicus Therapeutics Basic Information, Area Served and Competitors
    Table 48. Amicus Therapeutics Major Business
    Table 49. Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product and Services
    Table 50. Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 51. Amicus Therapeutics Recent Developments/Updates
    Table 52. Amicus Therapeutics Competitive Strengths & Weaknesses
    Table 53. Roche Basic Information, Area Served and Competitors
    Table 54. Roche Major Business
    Table 55. Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product and Services
    Table 56. Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 57. Roche Recent Developments/Updates
    Table 58. Roche Competitive Strengths & Weaknesses
    Table 59. Pfizer Basic Information, Area Served and Competitors
    Table 60. Pfizer Major Business
    Table 61. Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product and Services
    Table 62. Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 63. Pfizer Recent Developments/Updates
    Table 64. Pfizer Competitive Strengths & Weaknesses
    Table 65. NightstaRx Basic Information, Area Served and Competitors
    Table 66. NightstaRx Major Business
    Table 67. NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product and Services
    Table 68. NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 69. NightstaRx Recent Developments/Updates
    Table 70. NightstaRx Competitive Strengths & Weaknesses
    Table 71. MeiraGTx Basic Information, Area Served and Competitors
    Table 72. MeiraGTx Major Business
    Table 73. MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product and Services
    Table 74. MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 75. MeiraGTx Recent Developments/Updates
    Table 76. MeiraGTx Competitive Strengths & Weaknesses
    Table 77. Sarepta Therapeutics Basic Information, Area Served and Competitors
    Table 78. Sarepta Therapeutics Major Business
    Table 79. Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product and Services
    Table 80. Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 81. Sarepta Therapeutics Recent Developments/Updates
    Table 82. Sarepta Therapeutics Competitive Strengths & Weaknesses
    Table 83. Neurocrine Biosciences Basic Information, Area Served and Competitors
    Table 84. Neurocrine Biosciences Major Business
    Table 85. Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product and Services
    Table 86. Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 87. Neurocrine Biosciences Recent Developments/Updates
    Table 88. Neurocrine Biosciences Competitive Strengths & Weaknesses
    Table 89. Voyager Therapeutics Basic Information, Area Served and Competitors
    Table 90. Voyager Therapeutics Major Business
    Table 91. Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product and Services
    Table 92. Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 93. Voyager Therapeutics Recent Developments/Updates
    Table 94. Asklepios Biopharmaceutical Basic Information, Area Served and Competitors
    Table 95. Asklepios Biopharmaceutical Major Business
    Table 96. Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product and Services
    Table 97. Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
    Table 98. Global Key Players of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Upstream (Raw Materials)
    Table 99. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Typical Customers
List of Figure
    Figure 1. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Picture
    Figure 2. World Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Total Market Size: 2018 & 2022 & 2029, (USD Million)
    Figure 3. World Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Total Market Size (2018-2029) & (USD Million)
    Figure 4. World Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)
    Figure 5. World Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share by Region (2018-2029), (by Headquarter Location)
    Figure 6. United States Based Company Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (2018-2029) & (USD Million)
    Figure 7. China Based Company Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (2018-2029) & (USD Million)
    Figure 8. Europe Based Company Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (2018-2029) & (USD Million)
    Figure 9. Japan Based Company Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (2018-2029) & (USD Million)
    Figure 10. South Korea Based Company Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (2018-2029) & (USD Million)
    Figure 11. ASEAN Based Company Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (2018-2029) & (USD Million)
    Figure 12. India Based Company Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (2018-2029) & (USD Million)
    Figure 13. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Drivers
    Figure 14. Factors Affecting Demand
    Figure 15. World Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value (2018-2029) & (USD Million)
    Figure 16. World Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value Market Share by Region (2018-2029)
    Figure 17. United States Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value (2018-2029) & (USD Million)
    Figure 18. China Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value (2018-2029) & (USD Million)
    Figure 19. Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value (2018-2029) & (USD Million)
    Figure 20. Japan Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value (2018-2029) & (USD Million)
    Figure 21. South Korea Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value (2018-2029) & (USD Million)
    Figure 22. ASEAN Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value (2018-2029) & (USD Million)
    Figure 23. India Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value (2018-2029) & (USD Million)
    Figure 24. Producer Shipments of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy by Player Revenue ($MM) and Market Share (%): 2022
    Figure 25. Global Four-firm Concentration Ratios (CR4) for Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Markets in 2022
    Figure 26. Global Four-firm Concentration Ratios (CR8) for Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Markets in 2022
    Figure 27. United States VS China: Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share Comparison (2018 & 2022 & 2029)
    Figure 28. United States VS China: Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Consumption Value Market Share Comparison (2018 & 2022 & 2029)
    Figure 29. World Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type, (USD Million), 2018 & 2022 & 2029
    Figure 30. World Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Type in 2022
    Figure 31. Single-stranded AAV (ssAAV)
    Figure 32. Self-complementary AAV (scAAV)
    Figure 33. World Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Type (2018-2029)
    Figure 34. World Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application, (USD Million), 2018 & 2022 & 2029
    Figure 35. World Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Application in 2022
    Figure 36. Hemophilia
    Figure 37. Ophthalmology
    Figure 38. Lysosomal Storage Disorders
    Figure 39. Neurological Disorders
    Figure 40. Others
    Figure 41. Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Industrial Chain
    Figure 42. Methodology
    Figure 43. Research Process and Data Source

Research Methodology

Client Requirements

Review and analyze client requirements

Discussion of all the project requirements and queries

Flexibility Check

Project Feasibility Analysis

Finalizing tentative research programme

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

Determination of key drivers, restraints, challenge, and opportunity

Identifies market needs and trends

Market Size Estimation & Forecast

Estimation of historical data based on secondary and primary data

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

Consideration of geography, region-specific product/service demand for region segments

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

Data Source

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

Collection of data

Cumulating and collating the essential qualitative and quantitative data

Generation of report in client requested format by research analysts

Reviews by expert analysts

Final quality check

Clarifying queries

Receiving feedback

Ensuring satisfaction

01 Identification of data

This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
02 Evaluation of Market Dynamic

This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
03 Collection of Data

This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
04 Collaboration of Data

This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis

This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

Companies Mentioned

BioMarin Pharmaceutical
Sangamo Therapeutics
Amicus Therapeutics
Roche
Pfizer
NightstaRx
MeiraGTx
Sarepta Therapeutics
Neurocrine Biosciences
Voyager Therapeutics
Asklepios Biopharmaceutical

Related Reports

Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market 2023 by Company, Regions, Type and Application, Forecast to 2029

date 10 Jan 2023

date Pharma & Healthcare

AAV is transformed from a naturally occurring virus into a delivery mechanism for gene therapy. The viral DNA is replaced with new DNA, and it becomes a precisely coded vector and is no longer considered a virus, as most of the viral components have been replaced. The AAV Vector-Based Gene Therapy market size is anticipated to shoot up exponentially attributing to an increase in the approval of a growing number of gene therapies and readily adoption on approval, ability to treat a broad array of conditions, increasing prevalence of diseases, convenient one-time dosing approach and curative treatment options.

Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market 2024 by Company, Regions, Type and Application, Forecast to 2030

date 04 Jan 2024

date Pharma & Healthcare

According to our (Global Info Research) latest study, the global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market size was valued at USD 789.2 million in 2023 and is forecast to a readjusted size of USD 1123 million by 2030 with a CAGR of 5.2% during review period.

Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Supply, Demand and Key Producers, 2024-2030

Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Supply, Demand and Key Producers, 2024-2030

date 29 Feb 2024

date Pharma & Healthcare

The global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market size is expected to reach $ 1123 million by 2030, rising at a market growth of 5.2% CAGR during the forecast period (2024-2030).

Product Tags

Adeno-Associated Virus (AAV) Vector-Based Gene Therapy

GABA Supplements

L-carnitine Capsule

Opical Thrombin

Purchase Options

Single User License

USD4480.00

Multi User License

USD6720.00

Corporate Users License

USD8960.00

Add To Cart

Buy Now

Popular Product Keywords

AI
semiconductor
electron
5G
artificial intelligence
Battery
new energy
We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.

Speak to our analyst >>
Our Clients
What We Can Provide?

With better results and higher quality products,Our professional reports can achieve four things:
- Insight into the industry market information
- Analyze market development needs
- Prospects for future development
- Develop industry investment strategy
Digging deeper into global industry information and providing market strategies.

Contact Us >>